SCHEMBL3569836

SCHEMBL3569836

CS(=O)(=O)OCC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7354141 0.78 USP2 (0.46)
SCHEMBL3581693 0.77 CA1 (0.35)
SCHEMBL11284503 0.76
SCHEMBL900920 0.76
SCHEMBL6578001 0.76
SCHEMBL4652322 0.76
SCHEMBL27455492 0.75 USP2 (0.50)
SCHEMBL3569833 0.74
SCHEMBL9643006 0.74
SCHEMBL7348117 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1112252-A4 KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF ADOLOR CORP (US) 2004-07-14 EP claimed
EP-1112252-A1 KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF Adolor Corporation (US) 2001-07-04 EP claimed
WO-2000014065-A1 KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF ADOLOR CORPORATION (US) 2000-03-16 WO claimed
WO-2024124084-A1 METHODS OF ADMINISTERING BELUMOSUDIL FOR TREATMENT OF MULTIPLE MYELOMA KADMON CORPORATION, LLC (US) 2024-06-13 WO disclosed
WO-2024063770-A1 LIQUID FORMULATION OF BELUMOSUDIL KADMON CORPORATION, LLC (US) 2024-03-28 WO disclosed
WO-2024064757-A1 LIQUID FORMULATION OF BELUMOSUDIL KADMON CORPORATION, LLC (US) 2024-03-28 WO disclosed
WO-2024015067-A1 METHODS OF ADMINISTERING BELUMOSUDIL FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE KADMON CORPORATION, LLC (US) 2024-01-18 WO disclosed
WO-2024015066-A1 METHODS OF ADMINISTERING BELUMOSUDIL IN COMBINATION WITH CYP3A INDUCERS AND/OR PROTON PUMP INHIBITORS KADMON CORPORATION, LLC (US) 2024-01-18 WO disclosed
CN-110036007-A PYRIDINE COMPOUND 第一三共株式会社 2019-07-19 CN disclosed
CN-106999490-A The glutamine enzyme inhibitor of crystal form 卡利泰拉生物科技公司 2017-08-01 CN disclosed
US-8729269-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2014-05-20 US disclosed
EP-1664038-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY Wockhardt Limited (IN) 2006-06-07 EP disclosed
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED 2005-06-30 US disclosed
WO-2005054234-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED (IN) 2005-06-16 WO disclosed
EP-1112252-A4 KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF ADOLOR CORP (US) 2004-07-14 EP disclosed
EP-1112252-A1 KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF Adolor Corporation (US) 2001-07-04 EP disclosed
WO-2000014065-A1 KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF ADOLOR CORPORATION (US) 2000-03-16 WO disclosed
EP-0436612-A4 AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER 1992-05-20 EP disclosed
EP-0436612-A1 AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER AUSTRALIAN COMMERCIAL RESEARCH &amp; DEVELOPMENT LIMITED (AU) 1991-07-17 EP disclosed
WO-1990003399-A1 AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) 1990-04-05 WO disclosed